{"pre_text": ["selling , general , and administrative expenses selling , general , and administrative expenses increased to $ 65.2 million in 2010 from $ 52.9 million in 2009 due primarily to increases in compensation expense and recruitment costs , principally in connection with higher headcount in 2010 , and an increase in non-cash compensation expense for the reasons described above .", "cost of goods sold cost of goods sold in 2010 and 2009 was $ 2.1 million and $ 1.7 million , respectively , and consisted primarily of royalties and other period costs related to arcalyst ae commercial supplies .", "to date , arcalyst ae shipments to our customers have primarily consisted of supplies of inventory manufactured and expensed as research and development costs prior to fda approval in 2008 ; therefore , the costs of these supplies were not included in costs of goods sold .", "other income and expense investment income decreased to $ 2.1 million in 2010 from $ 4.5 million in 2009 , due primarily to lower yields on , and lower average balances of , cash and marketable securities .", "interest expense increased to $ 9.1 million in 2010 from $ 2.3 million in 2009 .", "interest expense is primarily attributable to the imputed interest portion of payments to our landlord , commencing in the third quarter of 2009 , to lease newly constructed laboratory and office facilities in tarrytown , new york .", "income tax expense ( benefit ) in 2010 , we did not recognize any income tax expense or benefit .", "in 2009 , we recognized a $ 4.1 million income tax benefit , consisting primarily of ( i ) $ 2.7 million resulting from a provision in the worker , homeownership , and business assistance act of 2009 that allowed us to claim a refund of u.s .", "federal alternative minimum tax that we paid in 2008 , and ( ii ) $ 0.7 million resulting from a provision in the american recovery and reinvestment act of 2009 that allowed us to claim a refund for a portion of our unused pre-2006 research tax credits .", "years ended december 31 , 2009 and 2008 net loss regeneron reported a net loss of $ 67.8 million , or $ 0.85 per share ( basic and diluted ) , for the year ended december 31 , 2009 , compared to a net loss of $ 79.1 million , or $ 1.00 per share ( basic and diluted ) for 2008 .", "the decrease in our net loss in 2009 was principally due to higher collaboration revenue in connection with our antibody collaboration with sanofi-aventis , receipt of a $ 20.0 million substantive performance milestone payment in connection with our vegf trap-eye collaboration with bayer healthcare , and higher arcalyst ae sales , partly offset by higher research and development expenses , as detailed below .", "revenues revenues in 2009 and 2008 consist of the following: ."], "post_text": ["."], "table": [["( in millions )", "2009", "2008"], ["collaboration revenue", "", ""], ["sanofi-aventis", "$ 247.2", "$ 154.0"], ["bayer healthcare", "67.3", "31.2"], ["total collaboration revenue", "314.5", "185.2"], ["technology licensing revenue", "40.0", "40.0"], ["net product sales", "18.4", "6.3"], ["contract research and other revenue", "6.4", "7.0"], ["total revenue", "$ 379.3", "$ 238.5"]], "table_ori": [["(In millions)", "2009", "2008"], ["Collaboration revenue", "", ""], ["Sanofi-aventis", "$247.2", "$154.0"], ["Bayer HealthCare", "67.3", "31.2"], ["Total collaboration revenue", "314.5", "185.2"], ["Technology licensing revenue", "40.0", "40.0"], ["Net product sales", "18.4", "6.3"], ["Contract research and other revenue", "6.4", "7.0"], ["Total revenue", "$379.3", "$238.5"]]}

Question: what percentage of total revenue was bayer healthcare in 2009?
Evidence:
table_3: ( in millions ) the bayer healthcare of 2009 is 67.3 ; the bayer healthcare of 2008 is 31.2 ;
table_8: ( in millions ) the total revenue of 2009 is $ 379.3 ; the total revenue of 2008 is $ 238.5 ;
Program: divide(67.3, 379.3)
Answer:
str_answer: 18%
exe_answer: 0.17743